-

Hims & Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health

A new specialty built to support each person’s unique, ever-changing biology, with real medical leadership at every step

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers (NYSE: HIMS) today announced the launch of Peptides+, a new specialty built around clinically-guided protocols designed to target health at the cellular level. After a clinical visit with a licensed provider, eligible customers may be prescribed a personalized treatment plan including up to five treatments at launch: Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine, depending on their needs as determined by their provider. Access to BPC-157 and TB-500 will follow, consistent with regulatory standards.

Until now, getting these types of medications has often meant relying on unreliable and unregulated online sellers, or a high-cost longevity clinic. Peptides+ offers customers more accessible care, backed by real medical leadership and with consistent clinical oversight, because optimizing health shouldn’t be a privilege of the few.

Every plan starts with a comprehensive intake of health history and goals, so a licensed provider trained in peptide therapies can assess each individual and, if appropriate, tailor a personalized protocol to their needs. Treatments are compounded in the U.S. and dispensed directly by licensed, U.S. pharmacies regulated by state boards of pharmacy and held to rigorous quality and safety standards. The care team follows up regularly and can adjust the plan as needed, because what someone needs now may not be what they need in a year, or in ten years.

“Peptides+ gives men a clinically guided, personalized plan built around their goals, backed by a licensed provider who understands these therapies,” said Anant Vinjamoori, MD, MBA, Chief Medical Officer of Hims. “Anyone investing in their health deserves to know exactly what they’re putting in their body, and to have dedicated support along the way.”

“Women are used to being told their fatigue, brain fog, and changing bodies are simply part of life, and many have had to advocate for themselves just to be heard,” said Jessica Shepherd, MD, MBA, FACOG, Chief Medical Officer of Hers. “We believe women deserve a more comprehensive and personalized approach to their health, one that considers their unique health history, evolving needs and individual goals. The emerging therapies in Peptides+ have exciting potential. Meaningful outcomes start with understanding the whole person, making informed, evidence-based decisions and ensuring women have trusted medical guidance and ongoing support at every stage of life.”

Peptides are short chains of amino acids that act as the body’s own signaling molecules, telling cells what to do, from energy and recovery to metabolism and focus. Peptide therapies aren’t new to medicine: for instance, insulin is a well-understood and well-established peptide therapy. What’s new is making it seamless to access these emerging peptides alongside clinical expertise.

Five U.S.-compounded treatments in the Peptides+ specialty are available at launch:

  • Sermorelin is a peptide that supports the body’s own growth hormone signaling, which plays a role in muscle, metabolism, and recovery.
  • NAD+ is a coenzyme that helps cells produce energy and repair DNA. Natural levels tend to decline with age.
  • Glutathione is a naturally occurring antioxidant that supports the body’s cellular defenses against oxidative stress.
  • Vitamin B12 supports energy production, red blood cell formation, and brain and nervous system health. Low levels can cause fatigue, weakness, and brain fog in people who are deficient.
  • L-Carnitine is made from amino acids and supports cellular energy function and how the body uses fat for fuel.

Peptides+ is available with Care+, which pairs treatment with a comprehensive insights and support experience. Customers receive access to twice a year lab testing to track their progress, unlimited support and ongoing check-ins from a dedicated Care Team, and the option to message providers trained in peptide therapy 24/7 with any questions. To give customers and their providers a baseline from day one, without an office visit, the Hims Men’s panel includes at-home blood collection and access to lab tests that provide insights across 22 biomarkers, including testosterone, vitamin D, and cholesterol. For those whose lab results indicate potential eligibility, Care+ customers can also connect with a provider to determine if a testosterone treatment may be right for them. The Hers Women’s panel tests 22 biomarkers across hormones, vitamins, and heart health, and marks the first time Hers is offering at-home blood collection for women.

Today is just the beginning. Hims & Hers plans to add more peptides and therapies to this specialty, and looks forward to offering BPC-157 and TB-500 consistent with regulatory standards.

To learn more about Peptides+, explore Hims & Hers.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health and wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

Cautionary Note Regarding Forward-Looking Statements

This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “anticipates,” “expects,” “intends,” “plans,” “decides,” “may,” “will,” “likely,” “potential,” “future,” “over time,” “coming,” “hope,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding the launch and availability of Peptides+, including the treatments available at launch and our plans to add additional peptides and therapies, including BPC-157 and TB-500, consistent with regulatory standards; the availability and expected benefits of Care+ and related lab testing and support offerings; and the potential effects of Peptides+ on our customers and our business. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions, and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control), and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the timing and logistical considerations related to the rollout of Peptides+ and the addition of new peptides and therapies, and the related customer response; the supply chain for the Peptides+ offering; the evolving clinical evidence and regulatory status of the peptide therapies we offer or plan to offer, and our ability to offer such therapies consistent with regulatory standards; other changes in the application, interpretation, and enforcement of healthcare, pharmacy, compounding, consumer protection, or privacy laws or regulations applicable to our business in the United States; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of November 18, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.

Contacts

Press Contact
Susan Cadrecha
press@forhims.com

Hims & Hers

NYSE:HIMS

Release Versions

Contacts

Press Contact
Susan Cadrecha
press@forhims.com

More News From Hims & Hers

Dr. Andrew Huberman Joins Hims & Hers Board of Directors

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading global health and wellness platform, announced the appointment of Andrew Huberman, Ph.D., to the company’s Board of Directors. Dr. Huberman is a world-renowned neuroscientist and tenured professor in the Departments of Neurobiology and Ophthalmology at Stanford University School of Medicine. He has authored or co-authored more than 75 peer-reviewed articles in respected scientific journals...

Hims & Hers Health, Inc. Reports Third Quarter 2026 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the third quarter ended September 30, 2026. “In healthcare, whoever owns the customer relationship wins, and that’s exactly what we’re building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them,” said Andrew Dudum, co-founder and CEO. “Everythin...

Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

INDIANAPOLIS--(BUSINESS WIRE)--Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform. The agreement brings together Lilly’s obesity med...
Back to Newsroom